Our Business Model & Pipeline
A B2B Business Model
Our platform technology and library of functionalities translate into a streamlined production pipeline for small and big pharma companies and other firms in the biotools/diagnostics ecosystem. This enables cost-effective, facile, simplified creation of multiple products with a bottom-up strategy that allows for precise, controlled, customizable formulations. Our B2B business model involves:
>> Platform licensing
>> Product generation & validation and licensing
>> Strategic partnerships for product (co)development and/or production with pharma companies with GMP capabilities
OUR VERTICALS
Detection
Our technology enables incorporation of multiple epitopes, or the synergistic combination of different binders for enhanced detection
Prevention
We are developing a next-gen vaccine platform for cost-effective, updatable, finely-tunable formulations and pandemic preparedness.
Treatment
We are generating stratified immunotherapies targeting neurodegenerative diseases
We have generated multiple proof of concepts for i) serological diagnostics through dissection and re-arrangement of immunodomiant epitopes for multivalent polytope display and ii) antigen recognition by combination multiple target binders. Our platforms allow for topologically optimized cargo display, to maximize binding and recognition through controlled cargo orientation and precise control of the nanobioparticles morphology.
Our preclinical proof of concept shows that our platform allows for the creation of libraries of functionalities (adjuvants and antigens) providing a simplified pipeline for combinatorial design generating vaccine candidates on-demand in under an hour. Our platform is safe and elicits robust immune responses. We are actively developing this vertical for i) respiratory viruses and ii) pandemic preparedness.
Our technollogy enables mimicking the quaternary conformations of specific targets by grafting target antigens onto our multivalent scaffods with controlled topology and symmetry. This enables elicitation of antibodies that recognize only the pathogenic conformations of proteins, such as alpha-synnuclein, for the creation of safe and effective immunotherapies against Parkinson disease.